Sign in
XTLB Stock Price, Chart, Stats & News
XTL Biopharmaceuticals Ltd.
Save
XTL Biopharmaceuticals Ltd. (XTLB) does not currently pay a dividend.
2.08M
Market cap
–
Current P/E
–
Forward P/E
XTLB chart
Fundamentals
Gross margin | 26.39% |
Operating margin | -349.45% |
Pretax margin | -207.98% |
Net margin | -179.16% |
Effective tax rate | 13.86% |
ROA | -9.45% |
ROE | -14.49% |
D/E | 0.03x |
Interest coverage ratio | -27.65x |
XTLB valuation
P/E | – |
P/S | 1.90x |
P/B | 0.19x |
P/CF | – |
P/FCF | – |
P/OCF | – |
PEG | -0.25x |
EV multiple | -1.86x |
About
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications.
Similar securities
Based on sector and market capitalization
Report issue